EMA makes new recommendations for Imbruvica, medicines with terlipressin over respiratory and cardiovascular risks
The EMA is handing out a new recommendation surrounding J&J and AbbVie’s cancer drug Imbruvica and some medicines containing terlipressin.
On Friday, the EMA’s safety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.